

Passion for Innovation.
Compassion for Patients.™



Daiichi Sankyo Europe
Our Commitment in Antithrombotics



Daiichi-Sankyo

Contents

Living our Purpose	04
Our R&D Highlights	06
Daiichi Sankyo in Europe	08
Daiichi Sankyo – Our Legacy in Thrombotic Diseases	09
Understanding Thrombosis	10
The Largest Antithrombotic Trials	12
A Changing Healthcare Landscape	14
Our Oncology Commitment	15
Major R&D Pipeline	16
We Share our Success	18



Living our Purpose


The Daiichi Sankyo Group is dedicated to the creation and supply of **innovative pharmaceutical products** to address diverse, unmet medical needs of patients in mature and emerging markets.

We are a **global pharmaceutical company** with approximately **16,000 employees** and a presence in more than **20 countries**. We have **pioneered leading pharmaceutical products**, including Adrenalin®, an adrenal cortex hormone agent.

In **2005**, Daiichi Sankyo was established through the **merger of two companies: Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.**

Sankyo was founded as Sankyo Shoten in **1899**; 14 years later the name changed to Sankyo Co., Ltd.

The roots of Daiichi Pharmaceutical Co., Ltd. go back to **1915**, when the company was founded as Arsemin Shokai.



Our R&D Highlights

In 1900, **Jokichi Takamine**, the first president of Sankyo Shoten, **isolated adrenalin**, the first pure hormone from the suprarenal gland.

Researchers from Sankyo Co., Ltd. discovered the first **HMG-CoA reductase inhibitor, pravastatin, the first lipid-lowering statin**, in 1973, and ten years later, discovered **troglitazone**, an **insulin sensitiser**, marking the discovery of the **glitazone class of medications**.

Researchers from Daiichi Pharmaceuticals Co., Ltd. discovered the broad-spectrum oral **antibacterial agent levofloxacin**, the first **third-generation quinolone** in 1985 and in the 1990s, developed **irinotecan**, which is now an established **colon cancer therapy**.



Daiichi Sankyo in Europe

Our company's roots in Europe extend back to the **1980s**, when Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. established offices in Düsseldorf, Germany.

In **1990** Sankyo Co., Ltd. acquired pharmaceutical company **Luitpold Werke** from Munich, Germany, with production facilities in Pfaffenhofen, Germany and Altkirch, France.

Daiichi Sankyo is one of the largest Japanese pharmaceutical companies in Europe.



Daiichi Sankyo – Our Legacy in Thrombotic Diseases

Daiichi Sankyo has been a **pioneer in the field of thrombotic diseases for more than half a century**. This commitment is reflected in two antithrombotic products currently available for patients, one **antiplatelet** and one **anticoagulant**, licensed for four indications:

- **Efient®** (prasugrel), a once-daily oral treatment which targets platelet aggregation in arteries, helps to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
- **LIXIANA®** (edoxaban), a once-daily oral, direct factor Xa inhibitor, is for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.



Understanding Thrombosis

A contributory factor to **1 in 4 deaths worldwide**, thrombosis is often the underlying cause of cardiovascular disorders including heart attacks, thromboembolic strokes and venous thromboembolisms¹.

As the **leading cause of death and disability**, the sheer scale of the problem caused by thrombosis presents a serious and multifaceted challenge.

Despite both worrying statistics and the unpredictable nature of the disease, there is **real hope for patients**. **Thromboses**, also known as clots, are largely **preventable with the right treatments** that address the different pathways of clot formation. By enrolling patients on a course of effective treatment, the risk of patients suffering from thrombosis and therefore major cardiovascular disorders can be significantly reduced.




Daiichi Sankyo – Quality Assurance in Antithrombotic Clinical Trials

We know how essential it is for patients and healthcare professionals to have full confidence in our products. That's why we **evaluate new treatments to the highest ethical standards**. Daiichi Sankyo products are only made available once they have been **evaluated through robust and high quality clinical trials**, including the **largest** in their respective fields.


That means our products are compared against standards of care, among a **broad range of patients, including those most at risk**.

We do this to reflect best clinical practice and **assure healthcare professionals of the dosing, safety and efficacy** when prescribing our products to their patients.



The Largest Antithrombotic Trials

- **ENGAGE AF-TIMI 48:** ENGAGE AF-TIMI 48 is the largest (21,105 patients) and the longest (median follow-up duration of 2.8 years) trial to date for stroke prevention in atrial fibrillation^{2,3}.
- **Hokusai-VTE:** Hokusai VTE is the largest (8,292 patients) study to date of a non-vitamin K antagonist oral anticoagulant (NOAC) in venous thromboembolism (VTE) that studied patients with DVT and/or PE^{4,5}.
- **TRITON TIMI 38:** TRITON TIMI 38 (13,608 patients) is the largest trial to date evaluating a potent platelet inhibitor in ACS-PCI to prevent major cardiovascular events⁶.



Daiichi Sankyo – Our Commitment in Thrombotic Diseases

Our promise to patients is to **continue expanding medical knowledge** of these treatments to help more patients with additional cardiovascular conditions be treated according to the best treatment procedure, such as **percutaneous coronary intervention (PCI), transcatheter aortic valve implantation (TAVI), cardioversion and catheter ablation.**

We are also committed to investigating the use of these treatments in other common and related diseases, **including cancer**, in order to reduce the burden of thrombosis.

A Changing Healthcare Landscape

We are increasingly moving towards a targeted, personalised care structure. Reducing the burden of treatment is a major area of focus, that's why we are always looking to develop **convenient, once-daily treatment options that are unimpeded by food intake and have few drug-drug interactions**. We believe this is critical to ensure adherence and optimal treatment results for patients, and to maintain healthcare professional satisfaction.

Our Oncology Commitment

Cancer is one of the most common causes of death in Europe with a **high and often unmet medical need**.

Each year **14 million people worldwide** are faced with a cancer diagnosis⁷.

As the European population ages, the incidence of cancer is also likely to increase.

Providing current and future patients with **innovative treatments** is our goal.

Our **oncology pipeline** comprises small-molecule and monoclonal antibody agents that target a variety of biologic pathways involved in cell growth.

These treatments are currently being investigated in **Phase II and III studies** for multiple indications.

We have also obtained **orphan drug designation** for some of our agents currently under investigation.

We never give up on behalf of patients and their families.



Major R&D Pipeline

As of March 2017. Recent updates can be found on our website:
www.daiichisankyo.com/rd/pipeline/development_pipeline/index.html

Therapeutic area	Phase 1	Phase 2	Phase 3	Application
Oncology	<ul style="list-style-type: none"> • DS-3032 (US/JP) (MDM2 inhibitor) • PLX7486 (US) (FMS / TRK inhibitor) • PLX8394 (US) (BRAF inhibitor) • DS-6051 (US/JP) (NTRK/ROS1 inhibitor) • PLX9486 (US) (KIT inhibitor) • DS-3201 (JP) (EZH1/2 inhibitor) • PLX73086 (US) (CSF-1R inhibitor) • PLX51107 (US) (BRD4 inhibitor) • DS-8895 (JP) (Anti-EPHA2 antibody) • DS-8273 (US) (Anti-DR5 antibody) • DS-5573 (JP) (Anti-B7-H3 antibody) • DS-8201 (JP/US) (Anti-HER2 ADC) • U3-1784 (EU) (Anti-FGFR4 antibody) • DS-1123 (JP) (Anti-FGFR2 antibody) • U3-1402 (JP) (Anti-HER3 ADC) 	<ul style="list-style-type: none"> • Patritumab (EU) (U3-1287 / Anti-HER3 antibody) • Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD inhibitor) • DS-1647 (JP) (Glioblastoma / G47Δ virus) 	<ul style="list-style-type: none"> • Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody) • Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody) • Vemurafenib (US/EU) (PLX4032 / Melanoma Adjuvant / BRAFinhibitor) • Quizartinib (US/EU/Asia) (AC220 / AML-2nd / FLT3-ITD inhibitor) • Quizartinib (US/EU/Asia) (AC220 / AML-1st / FLT3-ITD inhibitor) • Pexidartinib (US/EU) (PLX3397 / TGCT / CSF-1R/KIT/FLT3-ITD inhibitor) 	
Cardiovascular- Metabolics	<ul style="list-style-type: none"> • DS-1040 (Acute ischemic stroke / TAFIa inhibitor) • DS-2330 (Hyperphosphatemia) • DS-9231/TS23 (Thrombosis / α2-PI inactivating antibody) • DS-9001 (Dyslipidemia / Anti-PCSK9 Anticalin Albumod) 	<ul style="list-style-type: none"> • Esaxerenone (JP) (CS-3150 / DM nephropathy / MR antagonist) • DS-8500 (JP/US) (Diabetes / GPR119 agonist) 	<ul style="list-style-type: none"> • Edoxaban (JP) (DU-176b / AF / FXa inhibitor) • Prasugrel (JP) (CS-747 / Ischemic stroke / Antiplatelet agent) • Esaxerenone (JP) (CS-3150 / Hypertension / MR antagonist) 	<ul style="list-style-type: none"> • Edoxaban (ASCA etc.) (DU-176b / AF / FXa inhibitor) • Edoxaban (ASCA etc.) (DU-176b / VTE / FXa inhibitor)
Others	<ul style="list-style-type: none"> • DS-1971 (Chronic pain) • DS-1501 (Osteoporosis / Anti-Siglec-15 antibody) • DS-7080 (US) (AMD / Angiogenesis inhibitor) • DS-2969 (Clostridium difficile infection/GyrB inhibitor) • DS-5141 (JP) (DMD / ENA oligonucleotide) • VN-0102/JVC-001 (JP) (MMR vaccine) 	<ul style="list-style-type: none"> • Laninamivir (US/EU) (CS-8958 / Anti-influenza / out-licensing with Biota) 	<ul style="list-style-type: none"> • Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand) • Mirogabalin (JP/Asia) (DS-5565 / DPNP/ α2δ ligand) • Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand) • Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ- receptor regulator) <Injection> • CHS-0214 (JP) (Etanercept BS / Rheumatoid arthritis / TNFα inhibitor) • VN-0105 (JP) (DPT-IPV / Hib vaccine) • Laninamivir (JP) (CS-8958 / Anti-influenza / nebulizer) 	<ul style="list-style-type: none"> • Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ-receptor agonist)<Oral> • CL-108 (US) (Acute pain / Opioid μ-receptor agonist) Intradermal Seasonal • Influenza Vaccine (JP) (VN-100 / prefilled i.d. vaccine for seasonal flu) • VN-0107/MEDI3250 (JP) (Nasal spray flu vaccine) • Denosumab (JP) (AMG 162 / Rheumatoid arthritis / Anti-RANKL antibody)

We Share our Success

In Europe, Daiichi Sankyo contributes to the “**Little Hearts**” charity, which provides orphaned children in Eastern Europe with a better future.

In addition, we are dedicated to educating society and our employees about cardiovascular diseases and supporting them to live a healthy life.

This gives us the opportunity to make a difference for children in need, but also to live up to our responsibility as a pharmaceutical company.



References

1. World Thrombosis Day. Know Thrombosis. Available at: <http://www.worldthrombosisday.org/>. Accessed February 2017.
2. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2013;369(22):2093-2104.
3. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014;383(9921):955-962.
4. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med.* 2013;369(15):1406-1415.
5. Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. *Thromb Res.* 2014;133(6):1145-1151.
6. Wiviott S, Braunwald E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. *NEJM.* November 2007;357:2001-15.
7. World Health Organization (WHO), Fact Sheet Number 297.



Daiichi-Sankyo

Daiichi Sankyo Europe GmbH
Zielstattstrasse 48 81379 Munich,
Germany
Phone: +49-89-7808-0
www.daiichi-sankyo.eu